Venous thromboembolism (VTE) is an important cancer complication. Recent studies
suggest directacting oral anticoagulants (DOACs) are possible alternatives for this …

Venous thromboembolism (VTE) is an important cancer complication. Recent studies
suggest directacting oral anticoagulants (DOACs) are possible alternatives for this …

Background/Aim: Although direct oral anti-coagulants (DOACs) are as safe and effective as
conventional anticoagulants for treating venous thromboembolism (VTE), we have …

Purpose: To evaluate the use of direct-acting oral anticoagulants in patients with cancer and
venous thromboembolism (VTE) treated at Ochsner Medical Center with the intent of …

Aim: There is almost no study on direct oral anticoagulant (DOAC) for the treatment of
venous thromboembolism (VTE) in Japanese patients with advanced cancer. The aim of this …

This is a narrative review of the relevant literature on the epidemiology, pathogenesis, and
treatment of venous thromboembolism (VTE) in cancer patients. In accordance with actual …

Background The role of direct oral anticoagulants (DOACs) in the treatment of cancer-
associated venous thromboembolism (VTE) has recently been established in several pivotal …

Anticoagulation for cancer-associated venous thromboembolism (VTE) can be challenging
due to complications—including bleeding and potential drug–drug interactions with …

INTRODUCTION Anticoagulant management of cancer-associated thrombosis is
challenging since this patient population is concurrently at an increased risk for bleeding …

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in patients
with cancer. On the basis of results from randomized controlled trials, direct oral …